22 December 2016 - The decision means 6,890 people in England and Wales who suffer with the debilitating inflammatory disease could be treated.

Health watchdog NICE has agreed patients will now be able to access the drug, called Otezla on the NHS, bringing availability in line with Scotland.

Otezla works by targeting a protein (PDE4) involved in the process of inflammation - by reducing the activity of this enzyme, it can help to control the inflammation associated with psoriatic arthritis, and thereby reduce the signs and symptoms of the condition.

Read The Express article